Bank of New York Mellon
ACRV icon

Bank of New York Mellon’s Acrivon Therapeutics ACRV Stock Holding History

Bank of New York Mellon’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-27,635
Closed -$56.1K – 4139
2025
Q1 		$56.1K Hold
27,635
– – ﹤0.01% 4047
2024
Q4 		$166K Sell
27,635
-1,874
-6% -$13.6K ﹤0.01% 3985
2024
Q3 		$207K Sell
29,509
-7,123
-19% -$56.1K ﹤0.01% 3896
2024
Q2 		$212K Buy
36,632
+12,219
+50% +$98.4K ﹤0.01% 3924
2024
Q1 		$175K Sell
24,413
-382
-2% -$1.77K ﹤0.01% 3966
2023
Q4 		$122K Hold
24,795
– – ﹤0.01% 4052
2023
Q3 		$237K Hold
24,795
– – ﹤0.01% 3902
2023
Q2 		$321K Buy
24,795
+1,958
+9% +$23.7K ﹤0.01% 3796
2023
Q1 		$290K Buy
+22,837
New +$383K ﹤0.01% 3759

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of New York Mellon's ACRV Position: Q2 2025 in Review

Bank of New York Mellon sold out of Acrivon Therapeutics (ACRV) in Q2 2025, closing a stake of 27,635 shares — an estimated $56.1K sold.

Bank of New York Mellon first reported a position in ACRV in Q1 2023 and held it in 9 quarters. The position peaked at $321K in Q2 2023. 53 funds tracked by Wall St. Rank hold ACRV as of Q2 2025.

  • Bank of New York Mellon reported no remaining Acrivon Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bank of New York Mellon sold 27,635 Acrivon Therapeutics shares in Q2 2025, an estimated $56.1K.
  • Bank of New York Mellon first reported a position in Acrivon Therapeutics in Q1 2023 and held it in 9 quarters.
  • Bank of New York Mellon's Acrivon Therapeutics position peaked at $321K in Q2 2023.
  • 53 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2025.

Based on Bank of New York Mellon's 13F filing for Q2 2025, filed 5 Aug 2025.